Metropolitan Life Insurance Company (MetLife)’s Praxis Precision Medicines PRAX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-163	Closed	-$24.9K	–	2419
2022 Q1	$24.9K	Sell	163 -423	-72%	-$86.9K	﹤0.01%	1989
2021 Q4	$173K	Buy	586 +33	+6%	+$9.68K	﹤0.01%	2122
2021 Q3	$153K	Buy	+553	New	+$150K	﹤0.01%	2273
2021 Q2	–	Sell	-242	Closed	-$119K	–	2839
2021 Q1	$119K	Hold	242	–	–	﹤0.01%	2343
2020 Q4	$200K	Buy	+242	New	+$141K	﹤0.01%	1936

Other funds holding PRAX

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PRAX Position: Q2 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Praxis Precision Medicines (PRAX) in Q2 2022, closing a stake of 163 shares — an estimated $24.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PRAX in Q4 2020 and held it in 5 quarters. The position peaked at $200K in Q4 2020. 95 funds tracked by Wall St. Rank hold PRAX as of Q2 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining Praxis Precision Medicines position as of Q2 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 163 Praxis Precision Medicines shares in Q2 2022, an estimated $24.9K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Praxis Precision Medicines in Q4 2020 and held it in 5 quarters.
Metropolitan Life Insurance Company (MetLife)'s Praxis Precision Medicines position peaked at $200K in Q4 2020.
95 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2022, filed 11 Aug 2022.